Ticagrelor for myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction

Why this status

  1. 2 Apr 2026: Trial registered, NCT07507500
  2. 2 Sep 2026: Trial started, NCT07507500

The trials

NCT07507500: Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months

State
Under way
Phase
Phase 4
People
8,100 planned
Started
2 Sep 2026
Primary completion
Jul 2029
Arms
Ticagrelor 12 months DAPT, Ticagrelor abbreviated DAPT
Results
None posted
  1. 2 Apr 2026: Trial registered
  2. 2 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Brilinta, Brilique, Chewing Ticagrelor, Possia, Ticagrelor 180mg, Ticagrelor 45 mg, Ticagrelor 60mg, Ticagrelor 90mg, Ticagrelor 90mg for 6-month (immediately after PCI), Ticagrelor 90mg/60mg, Ticagrelor monotherapy, half-dose ticagrelor, low-dose ticagrelor.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.